Legislation


SF 2801 – Minnesota

Status: Inactive / Dead
Year Introduced: 2018
Link: https://www.revisor.mn.gov/bills/bill.php?b=Senate&f=SF2801&ssn=0&y=2017

PRESCRIPTION DRUG COST REVIEW AND RATE SETTING ACT: creates the prescription drug cost review commission and establishes rate-setting requirements. Would require a drug manufacturer to notify the commission if the manufacturer plans to increase the wholesale acquisition cost of a patent-protected brand name drug by more than $10,000 during any 12 month-period or intends to introduce to market a brand name drug that has a wholesale acquisition cost (WAC) of $30,000 per year or per course of treatment. Establishes a commission to review if spending on a prescription drug product creates excess costs. If the commission find excess spending, the commission shall establish the level of reimbursement that must be billed and paid among: (1) group purchasers and pharmacies; (2) wholesale distributors and pharmacies; and (3) pharmacies and uninsured consumers or consumers who are enrolled in a health plan but who have not yet met the health plan’s deductible.


Return to Database Search

© 2018-2019 The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found

Leave A Comment